Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
FPMAJ Calls for Post-Launch Premiums for Add’l Indications, Evidence
The government should grant post-launch premiums for listed products if their usefulness is demonstrated through additional indications or the accumulation of evidence data, the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) urges. The umbrella organ of Japan pharma trade…
To read the full story
Related Article
ORGANIZATION
- UA Zensen Manufacturing Wage Hikes at 4.89%, Pharma in Mid-4% Range
September 4, 2026
- LINK-J Eyes Stronger Ties with AI, Semiconductor Sectors
September 2, 2026
- JGA Unveils Industry Vision 2035, Eyes Sustainable Structure
September 2, 2026
- Ex-JMA Vice President Takashi Hanyuda Dies at 78
August 27, 2026
- Pharma Labor Group Logs Wage Hikes of around 4% at July-End
August 24, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…